Two months after merging with ReSearch Pharmaceutical Services to form the world's fourth-largest CRO, PRA is back on the buyer's block, snatching up the early-stage-focused CRI Lifetree.
This year's Fierce 15 offers some bright prospects from some great biotech minds. You'll find people--like serial entrepreneur and MIT scientist Bob Langer--offering bold if not radical technology from new companies like Moderna, and a whole slate of Big Pharma companies either already jumping in the game or looking to find out more.Some of this year's crop of biotechs should do fine.
Some of them won't. Anybody who tries to pick only winners among private biotechs is destined to fail. What we are sure of is that everyone in this year's group is trying to do something significant about serious diseases. And they stand a chance of doing well by doing good. Read the full report >>
As the industry's heavyweights, up-and-comers and all in between flooded the Boston Convention Center for the annual Drug Information Association meeting, FierceCRO was on hand to take the pulse of outsourcers, app developers and clinical data wonks as they brace for changing times in the service world. In the slideshow, take a look through Fierce's trip through DIA 2013 for a glimpse at where our industry stands and where some of its leaders think it's going. Check it out >
POPULAR COMMENT THREADS
Global R&D spending is unlikely to grow by much more than single digits over the next 5 years, but that won't do much harm to the world's biggest CROs, according to a Morningstar analyst, as the industry's heavyweights are only digging deeper into the operations of their sponsors.
Fresh off a $25 million IPO, Evoke is riding into Phase III with its gastroparesis-treating nasal spray, and now the biotech has recruited SynteractHCR to serve as its go-to CRO for the late-stage effort.
As CROs around the world weigh the benefits of developing their own therapies, South Korea's SillaJen has signed a deal worth up to $150 million to acquire former client Jennerex and inherit the company's Phase III-ready cancer vaccine.
CRO Aptuit has named Jonathan Goldman as its next CEO, recruiting a veteran from rival Icon and rounding out its executive suite after months of shakeups.
Contract developer Almac has signed a deal to license its technology to Genomic Health for breast cancer diagnostics, reaping $9 million with the chance for a bigger payday down the road.
Contract diagnostics outfit ResearchDx is making its way into India, counting on the boom in companion tests to drive demand for its services around the globe.
From Our Sister Sites
This didn't take long. Myriad Genetics' attorneys have struck again and filed a suit this time against LabCorp, barely two days after LabCorp launched a series of predictive cancer diagnostic tests focused on BRCA mutations.
Bloomberg reported that Intuitive Surgical has issued a recall affecting more than 1,300 robot arms of its da Vinci surgical around the world because they may be producing too much friction. When that happens, the da Vinci can choke during surgery and briefly stop working before it catches up.